BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 7175439)

  • 1. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the C3b receptor-binding domain in third component of complement.
    Becherer JD; Lambris JD
    J Biol Chem; 1988 Oct; 263(28):14586-91. PubMed ID: 2971659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues.
    Fries LF; Prince GM; Gaither TA; Frank MM
    J Immunol; 1985 Oct; 135(4):2673-9. PubMed ID: 3161945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
    Medof ME; Nussenzweig V
    J Exp Med; 1984 Jun; 159(6):1669-85. PubMed ID: 6233387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
    Medof ME; Prince GM; Mold C
    Proc Natl Acad Sci U S A; 1982 Aug; 79(16):5047-51. PubMed ID: 6214790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glomerular CR1 express in situ cofactor activity for degradation of C3b.
    Vedeler CA; Matre R; Iversen BM
    Int Arch Allergy Appl Immunol; 1990; 92(1):60-3. PubMed ID: 2147176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).
    Kinoshita T; Lavoie S; Nussenzweig V
    J Immunol; 1985 Apr; 134(4):2564-70. PubMed ID: 3156184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody.
    Holers VM; Seya T; Brown E; O'Shea JJ; Atkinson JP
    Complement; 1986; 3(2):63-78. PubMed ID: 2945695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin.
    Lambris JD; Dobson NJ; Ross GD
    J Exp Med; 1980 Dec; 152(6):1625-44. PubMed ID: 6450259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
    Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
    Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes.
    Kávai M; Rasmussen JM; Baatrup G; Zsindely A; Svehag SE
    Scand J Immunol; 1988 Jul; 28(1):123-8. PubMed ID: 2969612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleavage of membrane bound C3bi, an intermediate of the third component of complement, to C3c and C3d-like fragments by crude leucocyte lysosomal lysates and purified leucocyte elastase.
    Carlo JR; Spitznagel JK; Studer EJ; Conrad DH; Ruddy S
    Immunology; 1981 Oct; 44(2):381-91. PubMed ID: 7028603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc ions inhibit factor I-mediated release of CR1-bound immune complexes and degradation of cell-bound complement factors C3b and C4b.
    Jepsen HH; Teisner B; Svehag SE
    Scand J Immunol; 1990 Apr; 31(4):397-403. PubMed ID: 2139734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
    Koistinen V; Wessberg S; Leikola J
    Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.